RASSF1 and neuroblastoma: The hazard ratio of this analysis was 2.4 (95% CI, 0.6–9.2); although this association did not reach statistical significance, these findings show that the methylation status of RASSF1A in the serum of patients with neuroblastoma may have the potential to become a prognostic predictor of outcome.